Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | BCL6 | P41182 | 1/20 | 0.44 |
| ▸ | F2RL3 | Q96RI0 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | F2R | P25116 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30692937 | 1.00 | MAPT (0.48) | MAPTBCL6F2RL3MEN1LMNA | |
| SCHEMBL20568458 | 0.87 | MAPT (0.52) | MAPTBCL6F2RL3MEN1LMNA | |
| SCHEMBL30692912 | 0.81 | BCL6 (0.47) | MAPTBCL6F2RL3MEN1LMNA | |
| SCHEMBL23610898 | 0.81 | BCL6 (0.47) | MAPTBCL6F2RL3MEN1LMNA | |
| SCHEMBL23610837 | 0.80 | BCL6 (0.47) | MAPTBCL6MEN1KMT2A | |
| SCHEMBL26983080 | 0.80 | MAPT (0.47) | MAPTBCL6F2RL3MEN1LMNA | |
| SCHEMBL23610702 | 0.79 | MAPT (0.51) | MAPTBCL6F2RL3MEN1LMNA | |
| SCHEMBL20569209 | 0.77 | CD38 (0.50) | MAPTBCL6F2RL3MEN1LMNA | |
| SCHEMBL30692938 | 0.77 | MAPT (0.49) | MAPTBCL6F2RL3MEN1LMNA | |
| SCHEMBL23610667 | 0.77 | MAPT (0.49) | MAPTBCL6F2RL3MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630749-B9 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-4371562-A2 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-22 | — | — | EP | disclosed |
| EP-3630749-B1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-11161839-B2 | 2-quinolone derived inhibitors of BCL6 | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-11-02 | — | — | US | disclosed |
| US-20210206756-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161839-B2 | 2-quinolone derived inhibitors of BCL6 | BCL6, BCL6B, BCL3 | MAPT 4365/4885BCL6 1/4885F2RL3 1522/4885 |
| US-20210206756-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | MAPT 4365/4885BCL6 1/4885F2RL3 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.